Literature DB >> 8772606

Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood.

S Longobardi1, B Merola, R Pivonello, F Di Rella, C Di Somma, A Colao, E Ghigo, F Camanni, G Lombardi.   

Abstract

At present, the most appropriate method for diagnosing GH deficiency (GHD) in adults remains unclear. Recently, it has been demonstrated that GHD in adults can be identified by insulin tolerance test (ITT). Moreover, it has been described that the GHRH plus pyridostigmine (GHRH+PD) test is more accurate than an arginine, glucagon, levodopa, or GHRH test to diagnose GHD in adults. In the current study, firstly we reevaluated GH secretion by the GHRH+PD test in adults previously diagnosed as GH deficient in childhood. The study included 69 patients and 38 healthy subjects. After the GHRH+PD test, the patients and the healthy subjects had peak GH levels of 10.6 +/- 11.2 and 56.7 +/- 28.1 micrograms/L, respectively (P < 0.001). The patients were divided into two groups, responder patients and nonresponder patients, considering an arbitrary cut-off of 10 micrograms/L as the GH peak after the GHRH+PD test. Thirty-nine patients had GH peak below 10 micrograms/L (1.9 +/- 1.7 micrograms/L), whereas the remaining 30 patients above 10 micrograms/L (21.6 +/- 8.] micrograms/L; P < 0.001). Secondly, we compared the GHRH+PD test and the ITT in diagnosing GHD. Twenty-one of the 39 patients with a GH peak below 10 micrograms/L and 29 of the 30 patients with a GH peak above 10 micrograms/L after the GHRH+PD test underwent an ITT. The GH peak after insulin administration was 2.1 +/- 1.7 micrograms/L in nonresponder patients and 21.1 +/- 9.3 micrograms/L in responder patients after the GHRH+PD test (P < 0.001). Three of the responder patients to the GHRH+PD test were identified as GH deficient by the ITT. The relative diagnostic accuracies of the two tests to discriminate GH-deficient patients from healthy subjects were similar (ITT vs. GHRH test: sensitivity, 100%, specificity, 90%; GHRH+PD vs. ITT; sensitivity, 88%; specificity, 100%). In conclusion, in adults previously diagnosed as GH deficient, it is mandatory to reevaluate GH secretion. GHRH+PD and/or ITT are able to diagnose GHD in adults with similar accuracies. Taking into account the potential side-effects of the ITT, however, the GHRH+PD test is the most reliable and safe test to accurately diagnose GHD status in adults.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8772606     DOI: 10.1210/jcem.81.3.8772606

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors.

Authors:  A Colao; G Cerbone; R Pivonello; M Klain; G Aimaretti; A Faggiano; C Di Somma; M Salvatore; G Lombardi
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

Review 2.  Growth hormone treatment in adults with growth hormone deficiency: the transition.

Authors:  M E Molitch
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

3.  Is the persistence of isolated GH deficiency in adulthood predicted by anatomical hypothalamic-pituitary alterations?

Authors:  S Vannelli; B Stasiowska; J Bellone; G Aimaretti; S Bellone; T Avataneo; S Cirillo; L Benso
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 4.  Diagnosis and treatment of growth hormone deficiency in adults.

Authors:  Atil Y Kargi; George R Merriam
Journal:  Nat Rev Endocrinol       Date:  2013-04-30       Impact factor: 43.330

Review 5.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

6.  A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis.

Authors:  Nicholas A Tritos; Amir H Hamrahian; Donna King; Susan L Greenspan; David M Cook; Peter J Jönsson; Michael P Wajnrajch; Maria Koltowska-Häggstrom; Beverly M K Biller
Journal:  Eur J Endocrinol       Date:  2012-06-18       Impact factor: 6.664

7.  Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.

Authors:  S Longobardi; F Di Rella; R Pivonello; C Di Somma; M Klain; L Maurelli; R Scarpa; A Colao; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

8.  Early retesting by GHRH + arginine test shows normal GH response in most children with idiopathic GH deficiency.

Authors:  C Bizzarri; S Pedicelli; B Boscherini; G Bedogni; M Cappa; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2014-11-07       Impact factor: 4.256

9.  Short procedure of GHRH plus arginine test in clinical practice.

Authors:  G Aimaretti; S Bellone; C Baffoni; G Cornel; C Origlia; L Di Vito; S Rovere; E Arvat; F Camanni; E Ghigo
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

10.  Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas.

Authors:  A Colao; G Cerbone; P Cappabianca; D Ferone; A Alfieri; F Di Salle; A Faggiano; B Merola; E de Divitiis; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.